THAR
Tharimmune Inc.
NASDAQ: THAR · HEALTHCARE · BIOTECHNOLOGY
$3.23
+3.53% today
Updated 2026-04-30
Market cap
$177.09M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.68
Dividend yield
—
52W range
$1 – $9
Volume
0.6M
Tharimmune Inc. (THAR) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| R&D | $368732.00 | $847272.00 | $1.84M | $2.28M | $3.56M | $6.39M |
| SG&A | $625807.00 | $671879.00 | $1.37M | $4.60M | $5.90M | $6.04M |
| Operating income | $-994539.00 | $-1.52M | $-3.21M | $-6.88M | $-9.46M | $-12.43M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-1.45M | $-2.17M | $-1.38M | $-6.65M | $-9.15M | $-12.43M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-1.45M | $-2.09M | $-1.61M | $-6.88M | $-9.30M | $-12.21M |
| Interest expense | $75074.00 | $246534.00 | $831277.00 | $1.59M | $16505.00 | $13684.00 |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-1.53M | $-2.42M | $-2.21M | $-8.47M | $-9.32M | $-12.20M |
| Net income growth (YoY) | — | -58.5% | +8.7% | -284.0% | -10.0% | -30.9% |
| Profit margin | — | — | — | — | — | — |